The use of whole genome sequencing for tuberculosis public health activities in Australia: a joint statement of the National Tuberculosis Advisory Committee and Communicable Diseases Genomics Network

Ellen J Donnan, Ben J Marais, Chris Coulter, Justin Waring, Ivan Bastian, Deborah A Williamson, Norelle L Sherry, Katherine Bond, Vitali Sintchenko, Ella M Meumann, Kristy Horan, Louise Cooley, and Justin T Denholm, for the National Tuberculosis Advisory Committee and the Communicable Diseases Genomics Network

# Summary

The public health utility of whole genome sequencing (WGS) for Mycobacterium tuberculosis includes genome-wide mutation analysis for genotypic drug susceptibility testing (DST), strain identification, differentiation of tuberculosis (TB) relapse from re-infection, transmission cluster detection to guide targeted public health responses and detection of laboratory cross contamination. This has the potential to optimise individual patient care and provide better targeted TB control measures compared to previous MIRU-VNTR genotyping methods. High resolution genotyping of TB should allow better targeting of contact tracing interventions and prevention strategies. WGS will be useful in programmatic evaluation of clinical and public health TB programs through the identification of relapse and cluster analyses to assess effectiveness of contact tracing activities.

Characterising pathogens using WGS is usually less laborious and less expensive than traditional typing methods, and laboratory costs will likely further decrease as it is probable that WGS will soon reduce the need for routine phenotypic DST. However, resource, infrastructure and workforce (including information technology infrastructure and bioinformatics support) has limited implementation of WGS in some jurisdictions, though all mycobacterial reference laboratories in Australia have implemented WGS to some extent. Pathogen genomic data need to be integrated with clinical and public health data to realise their full value. Effective reporting strategies still need to be established, including analyses of key clinical variables and reporting of clusters over time, as well as processes for communicating clusters in a timely manner for public health benefit.

NTAC and CDGN consider it a future requirement for all jurisdictions to have:

* access to prospective WGS of TB isolates;
* WGS results incorporated into routine laboratory reporting systems;
* WGS results reported to clinicians and public health programs;
* WGS results integrated into the routine TB surveillance system;
* routine cross jurisdictional comparison of WGS data; and
* continued education for public health staff and clinicians.

Through increasing capacity for identification of transmission risk and opportunities to intervene and prevent reactivation, WGS will be an increasingly valuable tool for TB control and elimination in Australia.

# Background

Bacterial pathogen characterisation using whole genome sequencing (WGS) has four main applications: high-identification and assessment of strain relatedness; genotyping; detection of mutations conferring drug resistance; and virulence gene detection.1 WGS-based genotyping offers opportunities for enhanced detection and tracking of outbreaks and transmission events. The array of information from genomic sequencing has been described as having potential for ‘precision medicine’, and is already leading to ‘precision public health’.2 Within the public health sphere, the key applications of interest for Mycobacterium tuberculosis are antimicrobial resistance prediction and transmission surveillance. The basic biology of M. tuberculosis, with its lack of horizontal gene transfer, slow growth in culture, and the nature of tuberculosis (TB) disease with extended duration of treatment, make it an ideal target pathogen for utilising WGS given both the clinical and public health value.3

In Australia, molecular epidemiological typing of M. tuberculosis by the Australian Mycobacterium Reference Laboratory Network (MRLN) is considered standard for the initial isolate identified from every patient diagnosed with tuberculosis.4 At the time of publication of the current Australian laboratory guidelines for mycobacteriology testing, the approved method was mycobacterial interspersed repetitive unit–variable-number tandem repeat (MIRU-VNTR) typing.5 MIRU-VNTR genotyping in Australia can be used to rule out transmission links if types are different, but is limited by poor strain discrimination, especially among strains of M. tuberculosis commonly found among migrants, who account for 85–90% of TB cases.4 This makes accurate cluster identification problematic with strains that are highly monomorphic and poorly differentiated using MIRU-VNTR, such as Beijing lineage strains.6

The Communicable Diseases Genomics Network (CDGN) and the National Tuberculosis Advisory Committee (NTAC) have recognised M. tuberculosis as a priority organism for WGS in 2021–2022. A working group has been established comprising WGS personnel from each state and territory (and from New Zealand); two NTAC representatives; and the coordinator of the Australian Society of Microbiologists Mycobacterium Special Interest Group, representing the five Australian Mycobacterium Reference Laboratories (MRLs) and other mycobacteriology facilities. The working group has performed a scoping study of M. tuberculosis WGS capabilities and methodologies across Australia; has shared reporting formats for WGS results; and is organising quality assurance programs (QAPs) for participating laboratories. As of 2022, all jurisdictions either perform or have access to WGS capacity for M. tuberculosis, with extensive experience and capability in the larger eastern states. The working group aims to optimise reporting formats to local needs in each jurisdiction; to standardise methodologies where necessary; and to investigate interjurisdictional TB transmission using an integrated national genomics platform for rapid sharing and analysis of genomics data, such as Austrakka which has been used successfully for SARS-CoV-2 typing during the coronavirus disease 2019 (COVID-19) pandemic.

# Public health utility of WGS for TB

The key strength of WGS for M. tuberculosis is that it allows genome-wide mutation analysis for genotypic drug susceptibility testing, as well as lineage identification and cluster detection (using single nucleotide polymorphism (SNP) or core genome multi-locus sequence typing (cgMLST)), facilitating targeted public health responses. WGS also has high discriminatory power to recognise mixed infections with several strains of M. tuberculosis,3,7,8 and can detect laboratory cross contamination. This has the potential to optimise individual patient care and provide better targeted TB control measures.2,9

Accurate identification of transmission clusters, differentiating endogenous relapse from exogenous re-infection during disease recurrence, and detecting cases of laboratory cross-contamination using WGS has led to more precise disease classification and transmission detection compared to previous MIRU-VNTR genotyping methods.2,10 It has also been shown to have increased specificity over using MIRU-VNTR.2,3,11 Increased specificity conveys advantages of being better able to define local epidemiology and transmission, to identify previously unrecognised transmission, and to exclude suspected transmission.3 It also provides greater confidence when investigating potential laboratory cross contamination. WGS has also provided increased awareness of transmission of TB amongst Aboriginal and Torres Strait Islander communities, and of cross-border transmission, allowing for prioritised access to enhanced clinical and programmatic support in local communities.12,13

Currently, WGS is being undertaken on all primary M. tuberculosis isolates in some jurisdictions in Australia. Direct sequencing of M. tuberculosis from sputum smear positive samples is being undertaken in research settings, but it remains too expensive and cumbersome for routine clinical and public health use.2 Direct sequencing for clinical diagnosis and rapid drug susceptibility, with potential to significantly reduce turn-around times and the requirements for biosafety facilities,3,11 is likely to be a game changer for prompt effective treatment, but has many technical hurdles to overcome.

## Genomic drug susceptibility testing (DST)

Mutation analysis of M. tuberculosis bacteria, against a catalogue of known mutations conferring resistance to antibiotics used to treat TB, has the potential to give more rapid and complete information on drug resistance.3 A study in New South Wales that compared WGS with conventional phenotypic DST found WGS identified an additional 1% of isolates which were likely drug resistant; however, WGS provided a 20% increase in drug resistance detection in comparison with commercial genotypic assays by identifying mutations outside of the classic resistance determining regions in rpoB, inhA, katG, pncA and embB genes.14 Satta et al suggested genomic susceptibilities can be available within nine days of a positive culture compared with an average of three weeks with traditional phenotypic methods.11 More recent papers have suggested even faster turn-around times, with WGS information from early positive cultures where sequencing is routinely performed demonstrating result availability in a matter of days rather than weeks (particularly when second line drug susceptibility testing needs to be set up when initial resistance is detected from an isolate).2,3

Early identification of resistance patterns in patients with drug-resistant (DR)-TB will guide initiation of effective treatment, therefore reducing the infectious period of the patient and the risk of community transmission. It should allow a reduction in time spent in negative pressure isolation in hospital facilities, given that infectivity is rapidly terminated with the provision of highly effective treatment. Earlier effective treatment will also decrease the risk of development of further resistance whilst on treatment.

## Cluster investigation and transmission

Both Australian and international experience confirms that WGS supports enhanced investigations by more accurately defining clusters, and should be considered as the gold standard for assessment of transmission and strain relatedness.2 Using previous Australian standard methods, if two patients who recently migrated from a high TB incidence country presented with the same common MIRU-VNTR profile, genotyping has not been able to differentiate between recent transmission in Australia and reactivation of distant infection with a common strain from their homeland.4 Similarly, Bainomugisa et al demonstrated local community outbreaks with high genomic clustering among patients in the Torres Strait Protection Zone with WGS, including two probable cross-border transmission events of multidrug-resistant TB.12

The increased specificity of WGS clusters results in a reduced number of clusters to investigate. Gurjav et al found that the overall rate of MIRU-24 clustering was 20.1% (340/1,692) and was highest among Beijing lineage strains (35.7%; 168/470), and that there was limited transmission within identified clusters in New South Wales.15 In comparison, in New South Wales in 2018, the overall cluster rate using WGS was 9%, with 82% of clustered cases being born overseas.16 Early evidence suggested minimal transmission in most Australian settings;15 however, local transmission events amongst overseas-born people in Australia is being increasingly recognised.

WGS can provide evidence for probable transmission pathways, including a molecular clock of accumulation of random mutations,1,3 though sometimes is still insufficient to resolve transmission networks in TB outbreaks at the time.11 M. tuberculosis is an ideal organism for this purpose, as estimates for the genome mutation rate vary from 0.3 to 1.1 single nucleotide polymorphisms (SNPs) per genome per year.17 WGS thus can provide additional insights into transmission dynamics and can sometimes suggest missing or previously unidentified cases in clusters.2 SNP trees and SNP matrices can assist clinicians in understanding transmission pathways. This has included operational definitions of ≤ 5 SNP difference as a threshold for highly related strains (and therefore, potential transmission), although genomic information must always be interpreted in light of epidemiological and clinical context.18

## Investigation of TB recurrence

Sequencing of isolates from patients who have had a recurrence of TB can differentiate relapse from reinfection, which provides evidence to assess treatment adherence and efficacy, and overall information for evaluating program effectiveness.2,3,11 Shanmugam et al found that WGS provided increased resolution, but differentiation between relapse and reinfection was broadly consistent with MIRU-VNTR and spoligotyping in Indian TB patients.19 Given the significant proportion of Beijing lineage isolates with common MIRU-VNTR patterns in Australia, it has been shown programmatically that WGS is more useful for strain differentiation.20

## Laboratory cross contamination

Laboratory cross contamination can have significant costs and implications for individuals and the health system. False positive M. tuberculosis results can delay diagnosis and treatment of other conditions.9,21 It can also lead to unnecessary hospitalisation, laboratory testing, radiography, use of negative pressure rooms, and risks from potentially harmful treatments.9,21 This can also have significant psychological and social pressures on patients and their families. Fortunately, cross-contamination events remain uncommon in Australia. An international meta-analysis found two percent of all culture positive results were false positives secondary to laboratory contamination.21 It also found 9.2% of patients receive unnecessary and potentially harmful treatments. A Victorian study found a contamination rate of 0.7% in 2,298 samples using MIRU-VNTR.22

Genotyping using MIRU-VNTR has been used as the method to detect potential laboratory cross contamination; however, this method has been confounded by the common Beijing strains as for cluster detection. WGS has high discriminatory power to identify contamination events, and has enabled the detection of likely laboratory cross-contamination events with much greater precision than previous typing methods.23–25

# Genomic public health laboratory surveillance

A key surveillance objective for TB in Australia is to monitor the epidemiology of TB in Australia to better inform prevention strategies.4 High resolution genotyping of TB could/should allow better targeting of interventions to stop transmission.2 The increased specificity and indicators for transmission dynamics often allow the identification of local and inter-jurisdictional transmission, which can be used to implement prevention strategies and to guide contact tracing initiatives. WGS potentially allows for more targeted public health actions, preventing unnecessary investigations of false clusters.17 The international harmonisation of WGS methodologies and sequence reporting formats allows the analysis of Australian data in the local, national and global context and sharing of WGS with public health partners overseas when required.

The use of WGS and other methods of genomic DST are being incorporated into clinical care. The advantage of WGS over existing methods such as Xpert MTB-RIF Ultra assay (Cepheid), GenoType MTBDRplus and GenoType MTBDRsl assays (Hain Lifescience GmbH), is that WGS can investigate resistance to a broader range of drugs, as well as a wider spectrum of resistance-conferring mutations. However, these assays can currently be performed directly on clinical samples, providing rapid identification of resistance to key agents when used.

Characterising pathogens using WGS is usually less laborious and less expensive than traditional typing.2 Laboratory costs will likely further decrease in both materials and staffing, as it is probable that WGS will soon reduce the need for routine phenotypic DST. WGS has been shown to have high sensitivity and specificity for the first-line drugs isoniazid and rifampicin.11 Whilst routine phenotypic surveillance has not yet been ceased in Australia, it has in several overseas countries.2,26,27 It is important to note that any sequence-based method is unlikely to completely replace direct susceptibility testing for drug-resistant strains, as inferring drug susceptibility must rely on the continuous updating of databases correlating genotypic and phenotypic data.2

## Potential use for program evaluation

WGS is useful for elements of programmatic evaluation of clinical and public health TB programs. Identification of relapse in patients previously treated in Australia can flag review of regimen, duration and adherence which can provide important information in treating the relapsed disease. Cluster analysis can be used to assess effectiveness of retrospective identification, screening and use of preventive therapy in contact tracing activities, with systematic and pre-planned evaluation providing valuable opportunities for service strengthening.28

Communicating WGS evidence of recent transmission in migrant groups can be used to support arguments for use of preventive therapy over chest X-ray (CXR) surveillance in these groups. Investigation of potential laboratory cross contamination events can highlight breakdowns in laboratory processes,3 which can be used to implement more robust procedures to reduce potential contamination events. Identification of laboratory cross contamination provides an effective evaluation of laboratory processes.3

# Current challenges and limitation of WGS for TB

Resource, infrastructure and workforce limitations currently restrict WGS to jurisdictional public health laboratories, reference laboratories, and hospital infection control-affiliated laboratories.1 Information technology infrastructure and bioinformatics support are key components required for output that is useful to public health.2,11 Mycobacterial reference laboratories in Australia have all implemented WGS to some extent, though processes for prospective and retrospective sequencing differ. The use of WGS by diagnostic laboratories is likely to expand in the future.

Pathogen genomic data need to be integrated with clinical and public health data to realize their full value.2 Routine integration of WGS data into surveillance systems requires infrastructure for laboratory and public health systems to transmit and receive sequencing results; epidemiologists with the knowledge to interpret the laboratory data and integrate with the other available data; and clinicians to understand and communicate relevant results.2 Delivery of WGS information to TB doctors and nurses in a timely and understandable format is a key issue.11 Whilst WGS has been implemented to some degree across Australia, the ability of WGS to reduce TB transmission remains unproven.11 Therefore, ongoing monitoring and evaluation of the public health impact of genomic sequencing on TB control is warranted.

Effective reporting strategies for WGS still need to be established, including analyses of key clinical variables and reporting of clusters over time. Public reporting of WGS for TB in Australia is currently limited. WGS data has been included in the Tuberculosis in New South Wales Surveillance Reports since 2018, though challenges of communicating the data remain.16 Processes need to be implemented for communicating clusters in a timely and accurate manner, so as to be of public health benefit. One study detailed the contribution of real-time feedback between the microbiology laboratory and the TB control program prompting further contact investigations and identification of additional epidemiologically linked cases.10 As WGS becomes more routinely integrated into programmatic responses, it will be important to document and share the evidence of WGS impact on contact tracing activities in Australia.

Finally, as the technological and logistic integration of WGS becomes routine in programmatic TB management in Australia, there are a series of evolving ethical and legal questions which must also be considered. As discussed throughout this paper, WGS brings increasing capability for demonstrating evidence of the direction and timing of transmission, and for optimising performance of public health and clinical services. The community and organisational expectations that arise in parallel to these developments will likely necessitate updating public health practice, including considerations of access and use of personal and health data.Transparency and broad consultation will be critical to ensure that public health practices are aligned with both established and emerging community norms.

## Future requirements

NTAC and CDGN consider it a future requirement for all jurisdictions to have:

* access to prospective WGS of TB isolates;
* WGS results incorporated into routine laboratory reporting systems;
* WGS results reported to clinicians and public health programs;
* WGS results integrated into the routine TB surveillance system;
* routine cross jurisdictional comparison of WGS data; and
* continued education for public health staff and clinicians.

WGS results need to be incorporated into routine laboratory reporting systems; to be considered contextually through multidisciplinary review; and to be communicated clearly to clinicians and public health programs. Reporting schedules may vary jurisdictionally depending on the TB burden; appropriate reporting time frames from laboratory to public health would be considered to be weekly to a maximum of one month. Continued education for public health staff and clinicians is necessary to ensure the output of WGS is being maximised. WGS results need to be integrated into surveillance systems so analyses and reporting can be multifaceted and contemporaneous. Routine cross jurisdictional comparison of WGS data to detect Australia-wide clusters should be standard practice.

There needs to be continued collaboration between NTAC, CDGN, the Australian MRLs, and jurisdictional TB and public health programs through the various channels available. Communication of experiences (with implementation, utilisation for DST and cluster detection, and evaluation) has the potential to strengthen WGS throughout Australia.

Closer partnerships between genomics service providers, TB control programs and relevant clinicians are essential for achieving the vision outlined in this Statement. The ongoing translational research in developing and implementing culture-independent and metagenomic methods of drug resistance detection and subtyping should be supported. The Committees also support the development of sustained capacity for genomic testing in Asia-Pacific region.

Progression towards TB elimination is a stated goal for both the Australian and international TB communities.29,30 An important contribution towards elimination in low incidence countries is an aim for zero local transmission.31 Through increasing capacity for identification of transmission risk and opportunities to intervene and prevent reactivation, WGS will be an increasingly valuable tool for TB control and elimination in Australia.

# Notes

Ellen Donnan (Chair), Justin Denholm (Deputy Chair), Ben Marais, Chris Coulter, Justin Waring and Ivan Bastian are members of the National Tuberculosis Advisory Committee.

Ivan Bastian (Co-chair), Vitali Sintchenko (Co-chair), Chris Coulter, Deborah Williamson, Norelle Sherry, Katherine Bond, Ella Meumann, Kristy Horan, Louise Cooley, Ellen Donnan and Justin Denholm are members of the Communicable Diseases Genomics Network Tuberculosis working group.

This paper is endorsed by the Communicable Diseases Network Australia.

# Author details

Ellen J Donnan1   
Ben J Marais2,3   
Chris Coulter4,5   
Justin Waring6   
Ivan Bastian7   
Deborah A Williamson8,9   
Norelle L Sherry10,11   
Katherine Bond8   
Vitali Sintchenko3,12   
Ella M Meumann13,14   
Kristy Horan10   
Louise Cooley15,16   
Justin T Denholm9,17

for the National Tuberculosis Advisory Committee and the Communicable Diseases Genomics Network.

1. New South Wales Tuberculosis Program, Health Protection New South Wales, Sydney, Australia
2. The Children’s Hospital at Westmead, Sydney Childrens Hospital Network, Sydney, Australia
3. Sydney Infectious Diseases Institute (Sydney ID), The University of Sydney, Sydney, Australia
4. Communicable Diseases Branch, Queensland Department of Health, Brisbane, Australia
5. Queensland Mycobacterium Reference Laboratory, Pathology Queensland, Queensland Health, Brisbane, Australia
6. Western Australia Tuberculosis Control Program, North Metropolitan Health Service, Public Health Services, Perth, Western Australia
7. SA Pathology, Adelaide, Australia
8. Victorian Infectious Diseases Reference Laboratory (VIDRL), at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
9. Department of Infectious Diseases, Doherty Institute, University of Melbourne, Melbourne, Australia
10. Microbiological Diagnostic Unti Public Health Laboratory, Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection & Immunity, Melbourne, Australia
11. Department of Infectious Diseases, Austin Health, Melbourne, Australia
12. Institute of Clinical Pathology and Medical Research – NSW Health Pathology, Sydney, Australia
13. Royal Darwin Hospital, Darwin, Australia
14. Menzies School of Health Research, Darwin, Australia
15. Department of Microbiology and Infectious Diseases, Royal Hobart Hospital, Hobart, Australia
16. University of Tasmania, Hobart, Australia
17. Victorian Tuberculosis Program, Melbourne Health, Melbourne, Australia

# Corresponding author

Ms Ellen J Donnan

Chair, National TB Advisory Committee (NTAC)

NSW Tuberculosis and Rheumatic Heart Disease Program Manager

Health Protection NSW

LMB 2030 St Leonards NSW 1590

Ellen.Donnan@health.nsw.gov.au

# References

1. Kwong JC, McCallum N, Sintchenko V, Howden BP. Whole genome sequencing in clinical and public health microbiology. Pathology. 2015;47(3): 199–210. doi: https://doi.org/10.1097/PAT.0000000000000235.
2. Armstrong GL, MacCannell DR, Taylor J, Carleton HA, Neuhaus EB, Bradbury RS et al. Pathogen genomics in public health. N Engl J Med. 2019;381(26):2569–80. doi: https://doi.org/10.1056/NEJMsr1813907.
3. Kizny Gordon A, Marais B, Walker TM, Sintchenko V. Clinical and public health utility of Mycobacterium tuberculosis whole genome sequencing. Int J Infect Dis. 2021;113(Suppl 1):S40–2. doi: https://doi.org/10.1016/j.ijid.2021.02.114.
4. Australian Government Department of Health and Aged Care. Tuberculosis – CDNA National Guidelines for Public Health Units. [Internet.] Canberra: Australian Government Department of Health and Aged Care; March 2022. Available from: https://www.health.gov.au/resources/publications/tuberculosis-cdna-national-guidelines-for-public-health-units.
5. Bastian I, Shephard L, Lumb R, National Tuberculosis Advisory Committee (NTAC). Revised guidelines for Australian laboratories performing mycobacteriology testing. Commun Dis Intell (2018). 2020. 44. doi: https://doi.org/10.33321/cdi.2020.44.2.
6. Hanekom M, van der Spuy GD, Gey van Pittius NC, McEvoy CRE, Hoek KGP, Ndabambi SL et al. Discordance between mycobacterial interspersed repetitive-unit-variable-number tandem-repeat typing and IS6110 restriction fragment length polymorphism genotyping for analysis of Mycobacterium tuberculosis Beijing strains in a setting of high incidence of tuberculosis. J Clin Microbiol. 2008;46(10):3338–45. doi: https://doi.org/10.1128/JCM.00770-08.
7. Tarashi S, Fateh A, Mirsaeidi M, Siadat SD, Vaziri F. Mixed infections in tuberculosis: the missing part in a puzzle. Tuberculosis (Edinb). 2017;107: 168–74. doi: https://doi.org/10.1016/j.tube.2017.09.004.
8. Wyllie DH, Robinson E, Peto T, Crook DW, Ajileye A, Rathod P et al. Identifying mixed Mycobacterium tuberculosis infection and laboratory cross-contamination during mycobacterial sequencing programs. J Clin Microbiol. 2018;56(11):e00923-18. doi: https://doi.org/10.1128/JCM.00923-18.
9. Asgharzadeh M, Ozma MA, Rashedi J, Poor BM, Agharzadeh V, Vegari A et al. False-positive Mycobacterium tuberculosis detection: ways to prevent cross-contamination. Tuberc Respir Dis (Seoul). 2020;83(3):211–7. doi: https://doi.org/10.4046/trd.2019.0087.
10. Genestet G, Tatai C, Berland JL, Claude JB, Westeel E, Hodille E et al. Prospective whole-genome sequencing in tuberculosis outbreak investigation, France, 2017–2018. Emerg Infect Dis. 2019;25(3):589–92. doi: https://doi.org/10.3201/eid2503.181124.
11. Satta G, Lipman M, Smith GP, Arnold C, Kon OM, McHugh TD. Mycobacterium tuberculosis and whole-genome sequencing: how close are we to unleashing its full potential? Clin Microbiol Infect. 2018;24(6):604–9. doi: https://doi.org/10.1016/j.cmi.2017.10.030.
12. Bainomugisa A, Pandey S, Donnan E, Simpson G, Foster JB, Lavu E et al. Cross-border movement of highly drug-resistant Mycobacterium tuberculosis from Papua New Guinea to Australia through Torres Strait Protected Zone, 2010–2015. Emerg Infect Dis. 2019;25(3):406–15. doi: https://doi.org/10.3201/eid2503.181003.
13. Meumann EM, Horan K, Ralph AP, Farmer B, Globan M, Stephenson E et al. Tuberculosis in Australia’s tropical north: a population-based genomic epidemiological study. Lancet Reg Health West Pac. 2021;15:100229. doi: https://doi.org/10.1016/j.lanwpc.2021.100229.
14. Lam C, Martinez E, Crighton T, Furlong C, Donnan E, Marais BJ et al. Value of routine whole genome sequencing for Mycobacterium tuberculosis drug resistance detection. Int J Infect Dis. 2021;113(Suppl 1):S48–54. doi: https://doi.org/10.1016/j.ijid.2021.03.033.
15. Gurjav U, Outhred AC, Jelfs P, McCallum N, Wang Q, Hill-Cawthorne GA et al. Whole genome sequencing demonstrates limited transmission within identified Mycobacterium tuberculosis clusters in New South Wales, Australia. PLoS One. 2016;11(10):e0163612. doi: https://doi.org/10.1371/journal.pone.0163612.
16. Government of New South Wales Tuberculosis Program (NSW TB Program) Tuberculosis in NSW – Surveillance Report 2018. Sydney: Government of New South Wales Department of Health, Communicable Diseases Branch, NSW TB Program; December 2019. Available from: https://www.health.nsw.gov.au/Infectious/tuberculosis/Publications/2018-tb-report.pdf.
17. Nikolayevskyy V, Niemann S, Anthony R, van Soolingen D, Tagliani E, Ködmön C et al. Role and value of whole genome sequencing in studying tuberculosis transmission. Clin Microbiol Infect. 2019;25(11):1377–82. doi: https://doi.org/10.1016/j.cmi.2019.03.022.
18. Denholm J, Coulter C, Bastian I, NTAC. Defining a tuberculosis cluster or outbreak. Commun Dis Intell Q Rep. 2016;40(3):E356–9.
19. Shanmugam S, Bachmann NL, Martinez E, Menon R, Narendran G, Narayanan S et al. Whole genome sequencing based differentiation between re-infection and relapse in Indian patients with tuberculosis recurrence, with and without HIV co-infection. Int J Infect Dis. 2021;113(Suppl 1):S43–7. doi: https://doi.org/10.1016/j.ijid.2021.03.020.
20. Parvaresh L, Crighton T, Martinez E, Bustamante A, Chen S, Sintchenko V. Recurrence of tuberculosis in a low-incidence setting: a retrospective cross-sectional study augmented by whole genome sequencing. BMC Infect Dis. 2018;18(1):265. doi: https://doi.org/10.1186/s12879-018-3164-z.
21. Barac A, Karimzadeh-Esfahani H, Pourostadi M, Rahimi MT, Ahmadpour E, Rashedi J et al. Laboratory cross-contamination of Mycobacterium tuberculosis: a systematic review and meta-analysis. Lung. 2019;197(5):651–61. doi: https://doi.org/10.1007/s00408-019-00241-4.
22. Globan M, Lavender C, Leslie D, Brown L, Denholm J, Raios K et al. Molecular epidemiology of tuberculosis in Victoria, Australia, reveals low level of transmission. Int J Tuberc Lung Dis. 2016;20(5):652–8. doi: https://doi.org/10.5588/ijtld.15.0437.
23. Min J, Kim K, Choi H, Kang ES, Shin YM, An JY et al. Investigation of false-positive Mycobacterium tuberculosis culture tests using whole genome sequencing. Ann Thorac Med. 2019;14(1):90–3. doi: https://doi.org/10.4103/atm.ATM\_184\_18.
24. Kizny Gordon A, Tong SYC, Martinez E, Crighton T, Denholm JT, Sintchenko V. TB genomic surveillance and data sharing in recognising contamination events. Int J Tuberc Lung Dis. 2021;25(3):241–3. doi: https://doi.org/10.5588/ijtld.20.0740.
25. Wu J, Yang C, Lu L, Dai W. Detection of tuberculosis laboratory cross-contamination using whole-genome sequencing. Tuberculosis (Edinb). 2019;115:121–5. doi: https://doi.org/10.1016/j.tube.2018.10.012.
26. Allix-Béguec C, Arandjelovic I, Bi L, Beckert P, Bonnet M, Bradley P et al. Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing. N Engl J Med. 2018;379(15):1403–15. doi: https://doi.org/10.1056/NEJMoa1800474.
27. Meehan CJ, Goig CA, Kohl TA, Verboven L, Dippenaar A, Ezewudo M et al. Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues. Nat Rev Microbiol. 2019;17(9):533–45. doi: https://doi.org/10.1038/s41579-019-0214-5.
28. Ferdinand AS, Kelaher M, Lane CR, da Silva AG, Sherry NL, Ballard SA et al. An implementation science approach to evaluating pathogen whole genome sequencing in public health. Genome Med. 2021;13(1):121. doi: https://doi.org/1186/s13073-021-00934-7.
29. NTAC. The Strategic Plan for Control of Tuberculosis in Australia, 2016–2020: Towards Disease Elimination. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.10.
30. World Health Organization (WHO). Framework towards tuberculosis elimination in low-incidence countries. Geneva: WHO, Global Tuberculosis Programme; 18 March 2014. Available from: https://www.who.int/publications/i/item/9789241507707.
31. Marais BJ, Walker TM, Cirillo DM, Raviglione M, Abubakar I, van der Werf MJ et al. Aiming for zero tuberculosis transmission in low-burden countries. Lancet Respir Med. 2017;5(11):846–8. doi: https://doi.org/10.1016/S2213-2600(17)30382-X.

**Communicable Diseases Intelligence**

ISSN: 2209-6051 Online

**Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection, Department of Health and Aged Care. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.**

**Editor:** Noel Lally

**Deputy Editor:** Simon Petrie

**Design and Production:** Kasra Yousefi

**Editorial Advisory Board:** David Durrheim, Mark Ferson, Clare Huppatz, John Kaldor, Martyn Kirk, Meru Sheel and Steph Williams

**Website**: <http://www.health.gov.au/cdi>

**Contacts**CDI is produced by the Office of Health Protection, Australian Government Department of Health and Aged Care, GPO Box 9848, (MDP 6) CANBERRA ACT 2601

**Email:** [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au)

**Submit an Article**You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: <http://health.gov.au/cdi>.

Further enquiries should be directed to: [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au).

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2023 Commonwealth of Australia as represented by the Department of Health and Aged Care

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at [www.itsanhonour.gov.au](http://www.itsanhonour.gov.au/));
* any logos (including the Department of Health and Aged Care’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health and Aged Care or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health and Aged Care, GPO Box 9848, Canberra ACT 2601, or via e-mail to: [copyright@health.gov.au](mailto:copyright@health.gov.au)

**Communicable Diseases Network Australia**Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.  
<http://www.health.gov.au/cdna>